You are here

JNJ

Alex Gorsky to step down as J&J chair in 2023

Medical Marketing and Media

Thu, 12/1/22 - 10:57 am

J&J sues Amgen over plan to sell drug similar to Stelara

Business Insurance

Thu, 12/1/22 - 10:48 am

ulcerative colitis

J&J unit, happy with AC Immune Alzheimer's work, moves 1 of 2 shots to next step

Fierce Biotech

Thu, 12/1/22 - 10:33 am

Alzheimer's disease

Large pharmas probe takeover of Horizon Therapeutics

BioPharma Dive

Wed, 11/30/22 - 10:58 am

J&J Vision Sets Sights on Sustainability

Medical Devices and Diagnostics Industry

Wed, 11/30/22 - 10:39 am

Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint

Clinical Trials Arena

Sat, 11/26/22 - 07:17 pm

clinical trials

treatment-resistant depression

GSK, J&J and AZ top global drug access index, but foundation says plenty more work needs to be done

Fierce Pharma

Thu, 11/17/22 - 12:13 pm

Access to Medicine Foundation

Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court

Fierce Pharma

Tue, 11/15/22 - 10:32 am

copay asssistance programs

Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed

Motley Fool

Thu, 11/10/22 - 10:33 am

J&J vet Mammen wanted board influence to be Biogen's next CEO, but chairman said no

Fierce Pharma

Tue, 11/8/22 - 10:43 pm

J&J, Idorsia plan filings for aprocitentan data in resistant hypertension

Pharmaphorum

Tue, 11/8/22 - 10:33 pm

resistant hypertension

Ash 2022 preview – a new multiple myeloma mechanism makes a splash

EP Vantage

Sun, 11/6/22 - 01:23 pm

mutliple myeloma

Johnson & Johnson to Buy Abiomed for $16.6B

Medical Devices and Diagnostics Industry

Tue, 11/1/22 - 11:08 am

Janssen Steps Away from Phase I Prostate Cancer Study, Cites Patient Enrollment Issues

BioSpace

Mon, 10/31/22 - 04:14 pm

prostate cancer

clinical trials

J&J nabs FDA okay for BCMA bispecific Tecvayli

Pharmaphorum

Wed, 10/26/22 - 07:00 pm

Multiple Myeloma

New TREMFYA Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

Marketscreener

Tue, 10/25/22 - 10:53 am

clinical trials

ulcerative colitis

Boston Scientific, Edwards set to report Q3 results after ‘encouraging start’ to medtech earnings season

Medtech Dive

Tue, 10/25/22 - 10:46 am

Boston Scientific

Edwards Lifesciences

Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies

BioSpace

Wed, 10/19/22 - 10:44 am

Nucleome Therapeutics

precision medicine

autoimmune diseases

autoimmune disease

J&J’s $5bn projects have much to prove

EP Vantage

Wed, 10/19/22 - 10:37 am

Rybrevant/lazertinib

J&J holds off on volatile M&A market but has plenty of cash for a deal

Endpoints

Tue, 10/18/22 - 10:02 pm

Pages